2019 CABS Investor Forum

Date: January 9, 2019 @ 8:00 am – @ 1:00 pm
Location: Morrison & Foerster LLP, 425 Market Street, San Francisco, CA 94105-2482

If you register, please attend.  There are limited seats at Morrison & Foerster.  Each year many people are on the waiting list of CABS Investor Forum.

If something urgent arises, please cancel your registration ASAP online or send an email to info@cabsweb.org.

Registration is free.  Registration and photo ID are required to attend the forum.  Registration deadline is Jan 3, 2019.  

Chinese American BioPharmaceutical Society (CABS) is pleased to announce that 2019 CABS Investor Forum will be held on January 9th of 2019 in conjunction with JP Morgan Healthcare Conference. In 2018, pharmaceutical innovation, medical technology and healthcare continue to be the major areas of licensing and venture capital investment globally. This forum will feature two panel discussions joined by China- and US-based investors, business development executives, and entrepreneurs. The topics will focus on the US-Asia cross-border licensing and investment trends, opportunities and challenges in life sciences.


8:00am - 9:00am  Registration and Networking

9:00am - 9:10am  Welcome Remarks by Yan Wang, PhD, President, CABS

9:10am -10:10am  Panel Discussion

The policy trends, strategies, opportunities and challenges of investment in bio-pharmaceutical industry


Janet Xiao, PhD, JD, Co-Chair of Global Life Sciences Group, Morrison & Foerster LLP


Joseph Benkert, Senior Advisor, National Security, Morrison & Foerster LLP
Stella Xu, PhD, Managing Director, Quan Capital
Cheryl Cui, PhD, Partner of Nest.Bio Ventures

John Zhu, PhD, Partner, 6 Dimensions Capital 

10:10am -10:30am  Networking Break

10:30am - 11:30am  Panel Discussion 

Review and outlook for biopharmaceutical industry regarding investment, M&A and public offering in US and China including Hong Kong

Moderator:  Wendy Pan, PhD, Partner, Sidley


Wei Chang, MBA, Managing Director, Z-Park Fund

Jin Wang, PhD, Founding Partner of Manhattan Capital Group, Venture Partner of Puhua Capital

Mark Noguchi, MBA, Independent Advisor and Former Global Head, Roche Partnering

11:30am - 1:00pm Lunch and Networking


Introduction of Panelists

Joseph A. Bankert, Senior Advisor, National Security Group, Morrison & Foerster LLP

Joseph Benkert is a senior advisor in Morrison & Foerster’s National Security practice group. He advises clients on critical national security matters pertaining to the Committee on Foreign Investment in the United States (CFIUS), export controls, and various regulatory and compliance issues. Mr. Benkert previously served as a leading civilian official in the Department of Defense (DoD) under both the Bush and Obama administrations, including as Assistant Secretary of Defense for Global Security Affairs after being nominated by President Bush and confirmed by the Senate. While at the DoD, Mr. Benkert led the department’s involvement in numerous complex matters before CFIUS. Mr. Benkert’s responsibilities also included managing technology security policy, the reform of export control processes, numerous sensitive nonproliferation projects, and a broad range of other defense-related issues. More recently, Mr. Benkert served as a Vice President of a leading global consultancy group, under former Secretary of Defense William Cohen. Mr. Benkert was a career Navy officer with extensive experience both in operational command and in national security policy formulation and implementation.


Janet Xiao, PhD, JD, Co-Chair of Global Life Sciences Group, Morrison & Foerster LLP

Janet Xiao, PhD, J.D., is co-chair of the global Life Sciences Group of Morrison & Foerster LLP and specializes in world-wide patent procurement, patent portfolio management, and strategic planning for life sciences companies. Recognized for her deep understanding of the pharmaceutical and biotech industries and knowledge of IP relating to the life sciences arena (Chambers Global), Janet is highly sought after for complex patent strategic and IP due diligence work. She is instrumental on the strategy development for multibillion-dollar patent portfolios for pharmaceutical clients, and works extensively with U.S. and foreign life sciences clients in conducting IP due diligence in various business settings. Dr. Xiao is among the very few IP attorneys who are both equipped with solid skills in global strategic IP management and knowledgeable about IP issues unique to China and Chinese clients, and is frequently called upon to advise clients on IP issues and conduct IP due diligence in U.S./China cross-border transactions and operations in China.

Li Chen, PhD, Founder, Executive Director, Chief Executive Officer, and Chief Scientific Officer, Hua Medicine

Dr. Li Chen, Founder, Executive Director, Chief Executive Officer, and Chief Scientific Officer. leads Hua Medicine a clinical stage biotech company whose mission is to bring personalized diabetes medicines to patients in China and worldwide. He is a pioneer in collaborative innovation in China and advanced Hua Medicine with an operation principle of high standards, high quality and create high value. Hua Medicine leverages global resources to develop GKA and completed 6 clinical studies in China and USA, in which the HMS5552, a novel GK PAM demonstrated desirable safety and efficacy profiles together with an improvement of beta cell function in Chinese T2DM patients. Under his leadership, Hua Medicine completed successfully a POC study and initiated China NDA enabling process. During this period, Hua Medicine raised 200M USD and established the leading position of Hua Medicine in China biotech industry.

Li received his PhD at Iowa State University and joined Roche R&D center in USA in 1992. With 18 years at Roche, Li advanced his career from a medicinal chemist to the head of High Throughput Technology, and later CSO of Roche China R&D Center with a membership at Roche Research Leadership Team. He is an inventor of 35 granted patents and an author with over 60 publications.

Wenseng Pan, PhD, Partner, Sidley Austin LLP

Dr. Wenseng "Wendy" Pan is a leading life sciences lawyer and a partner of Sidley Austin LLP.  Her practice focuses on both public and private mergers and acquisitions, PE/VC financings and she is frequently involved in biotech companies’ pre-IPO restructuring and IPOs.  She has represented many well-known PE and VC funds, startup companies, growth stage and mature companies and multinational companies in a number of landmark transactions in the life sciences industry.  Her deep experience and unparalleled knowledge about the industry has enabled her to provide value-added services to her clients.  An active figure and leader in the US/China life sciences community, she has been recognized as a “deal broker” by BioWorld Today, by IFLR1000 as a leading lawyer and in Who’s Who Legal: Life Sciences (Transactional).  She is a member of the Board of Directors of The BayHelix Group.  Dr. Pan received her JD and PhD from Columbia University.  

Cheryl Cui, PhD, Partner of Nest.Bio Ventures 

Trained as a biomedical engineer, Cheryl’s interest is to identify promising technologies that address unmet clinical needs and work directly with founders during the venture building process. She was a former Venture Partner at VentureHealth, a Silicon Valley-based healthcare fund, where she coordinated portfolio companies’ growth strategy in the Asia Pacific. Cheryl previously co-founded a mobile health company, which was successfully acquired in 2012 and led to her selection as one of Canada’s Next 36. Cheryl was also selected one of the US Forbes 30 under 30s in 2018. She currently serves as a Board Member of Rootpath and HiFiBio Therapeutics.

Cheryl earned her joint PhD degree in Medical Engineering and Medical Physics from MIT and Harvard Medical School. Her research in building synthetic gene circuits and molecular systems have lead to publications in Science and Nature journals. Cheryl received her B.A.Sc. in Engineering Science and Biomedical Engineer from the University of Toronto.

John Zhu, PhD, Partner, 6 Dimensions Capital 

Dr. John Zhu, Partner of 6Dimensions Capital.  Prior to that, he worked for Wuxi Ventures, Greenwoods Asset, Applied Biosystems, etc.  Dr. Zhu has over 15 years of experience in health care industry.  He has led 20+ private equity investments, including CStone Pharma, Phoenix Healthcare Group, BGI, Gan&Lee, etc.  He earned his MBA from University of California at Berkeley and PhD from University of Massachusetts Medical Center.

Stella Xu, PhD, Managing Director of Quan Capital

Dr. Stella Xu is Managing Director of Quan Capital, a life sciences venture fund with offices in China & US, and deep expertise in cross-border value creation and global investments.  Prior to Quan, Dr. Xu was a core member of the global management team for Roche’s Immunology, Inflammation & Infectious Diseases areas, and VP/Site Head of Roche Innovation Center Shanghai.  From 2012-2017, she led the integrated research & early development site of ~200 scientists, successfully delivered a world-class innovative pipeline from Discovery to global Clinical Development in 3 years, and pioneered novel development strategies in China.  Prior to her R&D leadership role, Dr. Xu had extensive global business development and licensing experiences across deal types and disease areas.  After establishing the Roche Partnering office in Shanghai in 2008, she managed business development activities in APAC (ex-Japan).  She also led global due diligence transaction activities and managed key alliances from research collaboration to marketed products in Roche Partnering US for years.  Dr. Xu joined Roche from McKinsey US where she led management consulting engagements in diverse healthcare sectors and functional areas from R&D to commercialization.  Earlier in her career, Dr. Xu worked in biotech R&D in oncology & inflammation.

Dr. Xu received her PhD in Immunology from Northwestern University, and B.S. in Biophysics from Peking University.

Dr. Xu currently serves on the Board of ARMO BioSciences, Centrexion Therapeutics and Tempest Therapeutics.

Hai Mi, PhD, Managing Partner, Panacea Venture

Dr. Hai Mi is a Founding and Managing Partner of Panacea Venture. Prior to Panacea Venture, a life science VC focuses on early-stage investment and incubation, Hai joined Kleiner Perkins Caufield & Byers China as a Partner in 2015 and focuses on the firm’s life sciences practice.

Prior to joining KPCB China, Hai was a partner at DT Capital responsible for investment in life science, healthcare and other related fields. Hai was a venture partner of SB China Venture Capital (SBCVC) and his investment transactions include BGI, SyMap Medical and Precise Light.  Hai was Senior Director of Strategic Planning and then Vice President of Corporate Communications at WuXi Pharma Tech (NYSE: WX) in Shanghai where he played an important role in NYSE listing, and the acquisition of AppTec in US.  He also served on the board of Chemspec International (NYSE: CPC) as an independent board director and the chairman of audit committee, and he participated in the privatization of Chemspec.  Earlier Hai was a research scientist at Pfizer in the US.

Hai obtained a PhD in Organic Chemistry from New York University, an MBA from The University of Chicago Booth School of Business, and a B.S. in Material Science from Fudan University in Shanghai.

Cynthia Cai, (蔡小嘉) PhD; MBA; M. Eng., Senior Advisor, US Lead in Healthcare, Northern Light Venture Capital  

Dr. Cai is a senior advisor for Northern Light Venture Capital, a leading venture capital firm for Healthcare, TMT, and Advanced Technologies. She is focused on early-stage investments in the US healthcare segment. Dr. Cai had over 20 years of experience in leadership positions with one of the world’s most respected biotech companies. As senior director of marketing in the Mass Spec, Division for Agilent Technologies, she was responsible for global thought leader collaboration and solution development for its billion-dollar MS business. Before that, as business development manager and product marketing manager, Dr. Cai was involved in multiple acquisitions and divestitures and led a $500+ million-dollar flagship product development and its global commercialization. 

Dr. Cai earned a B.A. and Master of Engineering from Tsinghua University, received her PhD in Chemistry from the University of Massachusetts and her MBA from The Wharton Business School of the University of Pennsylvania. Dr. Cai served as Delaware governor economic advisor, a member of the Board of the Forum for Executive Women (FEW-DE). Dr. Cai has also been a mentor for Wharton EMBA, Tsinghua University Global MBA and Drexel LeBow School of Business for many years. She is a regular speaker at conferences such as Wharton China Business Forum, for topics related to cross-border commercialization and cross-culture career development.

Jin Wang, PhD, Founding Partner of Manhattan Capital Group, Venture Partner of Puhua Capital

Dr. Wang is an Angel investor & co-founder of famous Medical Social Network Company (丁香圆www.dxy.cn)  In late 90s, he joined Paramount Capital (USA), serviced as an Asia/Great China Regional Director, he also provided value-added service as a venture partner & executive for a portfolio company, PolaRx Biopharma. After that, he became a China Head for business & clinical development of a public company, Cell Therapeutic, Inc  In 2002, he return to China, started his own VC firm, MCG Group and invested more than 30 biotech or healthcare related company in China and US. Prior to his VC career, He worked for Roche in Oncology Group and Worcester foundation for Experimental Biology for basic research. He is co-founder of SAPA, very active in servicing biotech community and coaching startups  He obtained BS from Zhejiang University and Ph.D.in Biomedicine from WPI in US. 

Mark Noguchi, MBA, Independent Advisor

  Mark Noguchi is an independent advisor to small and large firms in the biotechnology/pharmaceutical sector.  He works with local and global companies addressing corporate strategies and business development. 

In 2018, Mark completed a 33-year career with the Roche Group.  Most recently he was Vice President and Global Head, Alliance and Asset Management, and also Global Head, Asia and Emerging Markets Partnering for Roche.

He oversaw the Roche staff of Global Alliance Directors, managing over 150 R&D through commercial-stage partnerships with Pharma companies, biotechnology firms, universities, and other healthcare entities, as well as the alliances with Roche Group members Chugai Pharmaceuticals, Flatiron Health, and Foundation Medicine, Inc.  Additionally, he managed the out-partnering of commercial and R&D assets. 

Mark led the Roche business development staffs located in Tokyo and Shanghai, establishing partnerships for innovative medicines from Asia countries and emerging markets. 

In other past positions at Roche, Mark held management roles in Roche business development, portfolio management, pharmaceutical marketing, regulatory affairs, and information technology.  He previously worked for a global consulting company and in academia.

Educated as a zoologist at the University of California, Davis, Mark received his MBA from UCLA’s Graduate School of Management.

Wei Cheng, MBA, Managing Director, Z-Park Fund

MBA of The Wharton School of the University of Pennsylvania  (Finance & Healthcare management); EMBA of PBC School of Finance, Tsinghua University (currently enrolled); M.S. in Chemistry, Rochester Institute of Technology; More than 20 years of experiences in finance and healthcare industries;Partner & MD of Z-Park Fund; Previous Director of IC of China Minsheng Investment Group (CMIG);Previous Director of office of the Board of Directors of China Minsheng Bank (CMB);

Mrs. Cheng has served at IBD of Credit Suisse (Asia), and BOC International (China), and led transactions of IPO, equity financing, M&A and debt financing for Chinese companies; served at EXELIXIS (a leading biopharmaceutical company in Silicon Valley, USA) for early oncology drug development.



Free Online Registration – $0 (USD)